Your browser doesn't support javascript.
loading
[Updates on rickets and osteomalacia: anti-FGF23 antibody, a new therapeutic approach for hypophosphatemic rickets/osteomalacia].
Shimada, Takashi.
Afiliación
  • Shimada T; Kyowa Hakko Kirin Co., LTD. Biologics Research Laboratories, Japan.
Clin Calcium ; 23(10): 1469-75, 2013 Oct.
Article en Ja | MEDLINE | ID: mdl-24076645
In the last decade, Fibroblast growth factor (FGF) 23 has been shown to be a causative factor of hypophosphatemic rickets/osteomalacia, and considered as potential therapeutic target for this disease. Now the most attention is paid to FGF23 blockades as a new category of therapy that may replace the current supplementation of phosphate and active vitamin D. In this chapter, pharmacological actions of the FGF23-neutralizing antibodies in murine hypophosphatemic rickets/osteomalacia model are reviewed. In addition, other types of FGF23 blockades are also briefly discussed.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Factores de Crecimiento de Fibroblastos / Raquitismo Hipofosfatémico Tipo de estudio: Prognostic_studies Idioma: Ja Revista: Clin Calcium Año: 2013 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Factores de Crecimiento de Fibroblastos / Raquitismo Hipofosfatémico Tipo de estudio: Prognostic_studies Idioma: Ja Revista: Clin Calcium Año: 2013 Tipo del documento: Article País de afiliación: Japón